Transcatheter Heart Valve Market Size Share Trends Forecast 2027

SEATTLE - Dec. 17, 2020 - PRLog -- Transcatheter aortic valve replacement (THVR) is approved for patients suffering from symptomatic severe aortic stenosis or regurgitation  is recommended for high risk patients suffering from other chronic diseases who need to undergo cardiac surgery.

Statistics:

The global Transcatheter Heart Valve Market is estimated to account for US$ 7,642.7 Mn in terms of value by the end of 2027

Global Transcatheter Heart Valve Market: Drivers

Increasing demand for minimally-invasive procedures is expected to boost growth of the global transcatheter heart valve market over the forecast period.

Global Transcatheter Heart Valve Market: Opportunities

Favourable reimbursement policies in various countries are expected to offer lucrative growth opportunities for players in the market. In the U.S., Medicare covers reimbursement for patients whose aortic heart valves are damaged and need replacement.

Global Transcatheter Heart Valve Market: Restraints

Clinical trials for transcatheter heart valve products are time consuming and require significant capital investment. Product failure in final phases of clinical trials can lead to major losses to the company.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/transcatheter-heart-valve-market-3380

Market Trends

For instance, in November 2019, Meril, a company based in India, announced that its MyVal-1 transcatheter heart valve demonstrated a high procedural success rate in a one-month clinical trial for patients at intermediate or high risk for surgical aortic valve replacement.

Increasing R&D in TAVR is expected to aid in growth of the market. For instance, in October 2019, researchers from University Heart Center Hamburg reported that implantation of the self-expanding Biovalve transcatheter heart valve for the treatment of severe aortic stenosis was safe.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3380

The PMA process is initiated by the medical device company with a series of meetings with FDA/CDRH focused on preclinical (bench and animal) testing as well as plans for a clinical trial.

Global Transcatheter Heart Valve Market: Key Developments

August 2019: Edwards Lifesciences announced to recall its SAPIEN 3 Ultra delivery system. The U.S. FDA identified this as a Class I recall

August 2019: Medtronic plc received the U.S. Food and Drug Administration approval for its Evolut TAVR system for patients with symptomatic severe native aortic stenosis who are at a low risk of surgical mortality

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3380